NCT01646073View on ClinicalTrials.gov

Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

425

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Plaque Psoriasis
Interventions
BIOLOGICAL

Adalimumab

adalimumab eow

BIOLOGICAL

placebo

placebo

Trial Locations (16)

100034

Site Reference ID/Investigator# 72888, Beijing

100044

Site Reference ID/Investigator# 72873, Beijing

100730

Site Reference ID/Investigator# 72887, Beijing

110001

Site Reference ID/Investigator# 72883, Shenyang

116011

Site Reference ID/Investigator# 72880, Dalian

200025

Site Reference ID/Investigator# 72876, Shanghai

200433

Site Reference ID/Investigator# 72875, Shanghai

250012

Site Reference ID/Investigator# 87058, Jinan

310003

Site Reference ID/Investigator# 72878, Hangzhou, Zhejiang

310009

Site Reference ID/Investigator# 72877, Hangzhou, Zhejiang

400038

Site Reference ID/Investigator# 72976, Chongqing

430022

Site Reference ID/Investigator# 72977, Wuhan, Hubei

510120

Site Reference ID/Investigator# 72973, Guangzhou

510630

Site Reference ID/Investigator# 72974, Guangzhou

610072

Site Reference ID/Investigator# 85693, Chengdu

710032

Site Reference ID/Investigator# 72975, Xi'an

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01646073 - Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis | Biotech Hunter | Biotech Hunter